PSMA recombinant proteins and antibodies

Prostate-specific membrane antigen (PSMA), also known as folate hydrolase 1 or glutamate carboxypeptidase II (GCPⅡ), is a type II transmembrane glycoprotein encoded by the FOLH1 gene located on the short arm of chromosome 11 in humans. In the past two decades, prostate-specific membrane antigen (PSMA) has been widely studied as a critical molecular target for prostate cancer (PCa). The unique molecular characteristics also make it possible to develop new PCa diagnostic and therapeutic methods. According to incomplete statistics, there are currently 162 radiopharmaceuticals targeting PSMA in the world, of which 74 are in the clinical stage, covering diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. Including 5 drugs that have been approved for marketing. More PSMA clinical research progress >>

DIMA BIOTECH is a biotechnology company focusing on preclinical research and development products and services for druggable targets. We can now provide a series of spot products targeting PSMA, including recombinant proteins, reference antibodies, biotin/PE fluorescent labeled antibodies and stable cell lines. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank for PSMA targets, which can screen out the lead antibody molecules required by customers in just 28 days. For more details, please contact us.